<GAIN FROM OUR PERSPECTIVE>

Franklin Biotechnology Discovery Fund  – 
BioDis : Newspaper symbol FBDIX : NASDAQ symbol Sector : Fund Category
Test-Drive Our Improved Fund Pages
Show me: Fund documents:
Portfolio1 : View Details
Fund Description2

The Fund invests at least 80% of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy and other select medical companies.

View Portfolio Holdings
Morningstar Style Box™
as of 03/31/2010
 
Net Assets (millions) 327.40
Class A as of July 31, 2009
Portfolio Managers
Evan McCulloch, CFA®
Joined Franklin Templeton in 1992
Managed Fund since 1997
Vincent W. Xiang
Joined Franklin Templeton in 2004
Managed Fund since 2004
Fund Highlights
as of July 31, 2010
Top 10 Holdings
Celgene Corp. 9.30%
Genzyme Corp. 8.40%
Amgen Inc. 7.90%
Gilead Sciences Inc. 7.50%
Alexion Pharmaceuticals Inc. 4.50%
Salix Pharmaceuticals Ltd. 3.90%
Biogen Idec Inc. 3.60%
Human Genome Sciences Inc. 3.50%
Onyx Pharmaceuticals Inc. 2.80%
Dendreon Corp. 2.50%
Asset Mix
as of July 31, 2010
(updated monthly)
Performance : View Details
Performance data quoted represents past performance, which does not guarantee future results. Current performance may differ from figures shown. Investment return and principal value will fluctuate with market conditions, and you may have a gain or loss when you sell your shares.
Expense Ratio and Sales Charge Information

Expense Ratio: 1.34%
Max. Initial Sales Charge: 5.75%
CDSC: 0.00%

Hypothetical $10,000 Investment as of 06/30/2010
$10,000 invested in the fund at inception, with all dividend and capital gain distributions reinvested, including sales charges, would be worth:
$21,354.00
Distributions : View Details  
Distribution amounts may be estimates.  
Dividend Frequency  
Annually  
Most Recent Fund Distributions
Distribution Amount
Long-term capital gains per share $0.188400
Distribution Schedule
Record date 12/14/00
Ex-Dividend date 12/15/00
Payable date 12/19/00
Reinvestment date 12/15/00
Fund Facts  
Inception date4 09/15/97
Fund number 402
CUSIP number 354 713 844
Minimum initial investment $1,000
Max. initial sales charge 5.75%
CDSC 0.00%
Expense ratio
as of September 01, 2010 (updated annually)		 1.34%
12b - 1 fees5 0.27%
Beta6
as of June 30, 2010 (updated quarterly)		 0.91
Fund Prices : Historical Prices as of 09/03/2010
Daily prices are the most current available.
NAV7 (Net Asset Value)
$60.25
NAV change (+/-) $0.61
POP8 (Public Offering Price)
$63.93
You need Adobe Acrobat Reader 6.0 or higher to view and print PDF documents.
Download free version from Adobe's website.

Important Legal Information

Franklin Biotechnology Discovery Fund is a non-diversified fund that concentrates in a single sector, which involves risks, such as patent considerations, product liability, government regulatory requirements and regulatory approval for new drugs and medical products. Biotechnology companies often are small, and/or relatively new. These smaller companies can be particularly sensitive to changes in economic conditions, have less certain growth prospects than larger, more established companies, and their stocks are often volatile. These and other risks are described more fully in the fund's prospectus.

Total Returns include change in share price, assume reinvestment of all distributions, and reflect the deduction of fund expenses and applicable fees. Total Returns With Sales Charge: returns reflect the deduction of the stated sales charges. Total returns, distribution rate, and yields reflect any applicable expense reductions, without which the results for those impacted funds would have been lower.

©2010 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not guarantee future results.

For more information on any of our funds, contact your financial advisor or download a free prospectus. Investors should carefully consider a fund's investment goals, risks, sales charges and expenses before investing. The prospectus contains this and other information. Please read the prospectus carefully before investing or sending money.

Footnotes

  1. Portfolio holdings are subject to change.
  2. All of the funds are subject to certain risks. Generally, investments offering potential for higher returns are accompanied by a higher degree of risk. Stocks and other equities representing an ownership interest in a corporation have historically outperformed other asset classes over the long term, but tend to fluctuate more dramatically over the short term. Bond prices are affected by interest rate changes. Bond prices, and thus a bond fund's share price, generally move in the opposite direction of interest rates. As the price of bonds in a fund adjust to a rise in interest rates, the fund's share price may decline. High-yield, lower-rated (junk) bonds generally have greater price swings and higher default risks. Foreign investing, especially in emerging markets, has additional risks such as currency and market volatility and political and social instability. These and other risks pertaining to specific funds, such as those involving investments in specialized industry sectors, such as the technology sector, which has been among the most volatile sectors in the market, or use of complex securities, are discussed in each fund's prospectus.
  3. After-tax average annual total returns represent the average change in value of an investment on an annualized basis. Returns are calculated using the highest individual federal income tax rates; state and local taxes are not considered. Your actual after-tax returns depend on your particular tax situation and may differ from those shown. The before shares sold calculation assumes taxes are paid on fund distributions (dividends and capital gains) but does not reflect taxes that may be incurred upon sale or exchange of shares. The after shares sold calculation also adjusts for taxes due if the fund investment is sold at the end of the measurement period.
  4. For performance reporting purposes, the inception date for Classes A, R, Z and Advisor Class shares of all Franklin Templeton Funds is the date of effectiveness of the fund's registration statement or the first day the fund commenced operations. For Classes B and C shares, except as subsequently noted, the inception date is the first day the fund commenced offering such shares. Franklin Income Fund Class B uses the inception date of the old Class B shares, renamed Class B1. For Mutual Series Funds and Franklin International Small Cap Growth and Franklin Large Cap Equity Funds, the inception date for Classes A, B, C and R shares is the funds' oldest class', Z or Advisor, inception date.
  5. Represents the maximum amount of Rule 12b-1 distribution and service fees the Fund may pay.
  6. A measure of the fund's volatility relative to the market, as represented by the S&P 1500 HealthCare Price Index. A beta greater than 1.00 indicates volatility greater than the market. Based on the 3-years ended as of the date of the calculation.
  7. The amount per share you would receive if you sold shares that day.
  8. Purchase price for each share of the fund on a given day. It includes the maximum initial sales charge, if any.

For U.S. residents only.